Immedica - Stockholm

Immedica is a rapidly expanding private pharmaceutical corporation headquartered in Stockholm, Sweden. It has a wide-reaching commercial presence throughout Europe and the Middle East, bringing extensive experience and know-how from the marketing of niche/specialty care products. The company's management team has a proven track record of success when it comes to the international sale of niche pharma products. Immedica has the capability to provide optimal access to specialty care medicines for those with serious medical needs, including areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing and reimbursement, quality, and product distribution. Its primary investor is Impilo AB, a private Nordic investment firm established in 2017 with more than 3.6 billion SEK in committed capital from prominent Nordic and international investors.